Auxilium Pharmaceuticals Inc. (AUXL)

[surf1944]

7:31AM Auxilium Pharma presented data at the ASSH Annual Meeting About XIAFLEX; 42% of joints previously treated successfully with XIAFLEX exhibited disease recurrence at year 4 (AUXL) 18.34 : Co announced results from Year 4 of the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study. These data indicated that the overall recurrence rate at Year 4 was 42.1 percent for patients previously treated successfully with XIAFLEX for Dupuytren's contracture.

The study assessed 623 joints in adult Dupuytren's patients with a palpable cord from earlier Auxilium studies, indicating that 57.9 percent of patients previously successfully treated with XIAFLEX did not experience disease recurrence based on the study's definition.

In the CORDLESS study, recurrence was defined as a 20 degree change of contracture with a palpable cord or when the treated joint underwent medical/surgical intervention. These data were highlighted as an oral presentation on October 5, 2013, at the 68th Annual Meeting of the American Society for Surgery of the Handn San Francisco, California.

Of the 623 joints that were successfully treated with XIAFLEX, only 12.8 percent of those joints received medical or surgical intervention through Year 4. Of the joints that received medical or surgical intervention by Year 4 of the study, patients were most commonly retreated with XIAFLEX.

Additional highlights from Year 4 of the CORDLESS study include: The overall recurrence rate increased by 15.4 percent between year two and three (19.6 to 35 percent) and increased by 7.1 percent from year three to four (35 to 42.1 percent). This represents a slowing of the recurrence rate in XIAFLEX treated patients over time. At four years, 87.2 percent of the 623 joints that achieved clinical success did not have a further surgery or other medical intervention. High severity proximal interphalangeal joints (those with baseline contractures > 40 degrees) had a higher recurrence rate than low severity PIP joints (71 percent versus 58 percent, respectively) at four years. Recurrence rates in successfully treated metacarpophalangeal joints with low severity (those with baseline contractures < 50 degrees) and high severity were comparable at four years (36 percent and 29 percent, respectively).